A batch of non-base drugs is restricted in use

With the continuous reform of medical insurance payment methods such as payment by disease and total advance payment, from the point of view of ensuring supply and guiding clinical rational drug use, the guidance of the base drug catalogue will be stronger and stronger, which will promote the release of included varieties to a certain extent.
1, the use of non-base drugs limited recently, a "on the collection of national-based varieties of demand notice" in the industry.
A hospital in Guangdong Province issued a statement saying: According to the National Health and Health Commission, the State Administration of Traditional Chinese Medicine "on further strengthening the management of the use of basic drugs in public medical institutions", "Guangdong Provincial Health and Health Commission and other five departments on the issuance of the overall promotion of the implementation of the national basic drug system" and other documents, public medical institutions at all levels in principle procurement and use of the national basic drugs ratio of not less than 40%, the use of the amount of not less than 30%.
this year, the proportion of the hospital's base drug equipped varieties is 31.73 percent, the amount of the use of the base drug accounted for 25.7 percent, are not up to standard.
in line with the policy of giving priority to the use of national essential drugs, the need for replacement of national-based varieties is being solicited from clinical departments.
requires that within the scope of the specialty, if the variety is non-national base, can write an application to change the same common name of the national base variety for replacement, the application form can be downloaded in the pharmacy department documents, each department by December 30, 2020 to fill out and submit to the Pharmacy Section.
from 31.73 percent of the existing proportion to 40 percent of the requirements of the proportion, generally the public triple-A hospital has an average of 1000-1400 varieties, the triple-A hospital or there are hundreds of varieties need to be replaced with the base drug species.
October, also in Guangzhou, a people's hospital issued a "notice on the limited use of non-base drugs", in order to further control the unreasonable increase in drug costs, by the Pharmaceutical Management and Pharmacology Committee research decision, from October 2020 on the hospital in use of non-base drugs to implement limited use.
specific limited measures are: auxiliary drug use, Foshan City medical institutions focus on monitoring the drug catalog (2018 edition), the monthly limit of 10,000 yuan / product regulations;
the amount of limited varieties is calculated from the 1st of each month, the use of the drug is suspended when it is used up in the current month, and the use status of the drug is re-enabled on the 1st of the next month.
In September, the minutes of a meeting of a hospital in Guangdong Province showed that "the use of the top single-variety drugs by amount of limited procurement, the limit of 75,000 yuan for base drugs, 55,000 yuan for non-base drugs" was revised to "the use of the top single-variety non-base drugs by amount of limited procurement, non-state-based drug limit of 40,000 yuan." At the beginning of
, a public hospital in Shenzhen published 148 varieties of "2020 elimination of non-national basic drug varieties catalog", human haemoglobin, Changchun statin injection, injection with serum yellow, injection with cerebroprotein hydrolysis and other large varieties are on the list.
in fact, Guangdong Province hospitals so actively adjust the use of base drugs, from the province's requirements for the proportion of basic drugs: Guangdong primary to three-level hospitals, the proportion of the number of base drug procurement varieties has been increased to 60%, 50%, 40%, the amount of use increased to 50%, 40%, 30%.
guangdong also proposed that medical institutions if two consecutive years of base drug ratio, use is not up to standard, will not be rated first.
2, the base drug catalog, coming? Guangdong, a major pharmaceutical province, has continuously strengthened and improved the use of base drugs, which is a clear signal to the industry: In fact, the adjustment of the basic drugs information has been frequently sent: last month, according to industry sources, the relevant departments have organized a basic drug catalog management method revision workshop, invited Hebei, Shanxi, Inner Mongolia, Jilin Shanghai, Jiangsu, Shandong, Henan and other 16 provinces (municipalities) Health and Human Rights Commission Pharmaceutical Administration Office (the lead office of drug administration work), the Commission Drug Management Center and relevant experts, to promote the basic drug catalog management methods revision work, which means that the basic drug catalog management methods have been officially launched.
July this year, the relevant content of the meeting of the base drug catalog flowed out, in accordance with the spirit of the meeting, is currently revising the management methods of the base drugs, and the management methods will be introduced to adjust the catalog accordingly.
From the point of view of time progress, although this year will not start the adjustment of the base drug, but the three-year cycle has reached the last year, the management method of the base drug catalog has been moved, it is expected that the adjustment of the base drug catalog will be the work of the relevant departments next year.
In fact, with the two insurance and one, graded diagnosis and treatment, grass-roots equipped with a certain proportion of non-base drugs and other policies, the characteristics of the base drug is no longer obvious, the role of the base drug catalog is weakened invisibly, but it is still one of the enterprises seeking to enter the directory.
to the latest expanded list of base drugs in 2018, a total of 120 new pharmaceutical varieties of Western medicine, 2017 sample hospital sales totaled 35.569 billion yuan, estimated at 1:4 ratio, corresponding to the actual market space of nearly 150 billion yuan. The criteria for the transfer of
catalogues are also relatively clear, combining disease spectrum, morbidity, disease burden, etc., to meet the needs of common diseases, chronic diseases and basic drug use in the areas of heavy burden, serious diseases and critical diseases, public health, etc., and to select appropriate essential drugs from medicines already on the market in China; The development of Chinese medicine industry supports the development and innovation of the pharmaceutical industry, tilting towards traditional Chinese medicine (including ethnic medicine) and domestic innovative medicine, and on the basis of covering the main clinical diseases, focusing on cancer, children, chronic diseases and other diseases, the new varieties include 12 kinds of anti-tumor drugs, 22 kinds of clinically in urgent need of children's medicine.
The above criteria are also obviously reflected in the number of selected varieties, cardiovascular disease drugs and hormones and endocrine drugs affect the two major categories of the largest number, respectively, 17 and 14, and these two varieties are covering high blood pressure, hyperlipidemia, diabetes and other chronic diseases with the highest incidence in China, reflecting the fundamental characteristics of the base drug "to protect the public."
, because targeted therapy has become a basic requirement for cancer treatment, there are also six targeted drugs on the list. the linkage between the
-based drug catalogue and the medical insurance catalogue is noteworthy, and the medical insurance department prioritizes the therapeutic drugs in the list of eligible essential drugs into the scope of the medical insurance catalogue or adjusts the classification of A-B, and enterprises can obtain the green channel of the health insurance catalogue by seeking access to the list of basic drugs.
research institutions believe that a more obvious trend in the list of essential drugs is to strengthen the clinically necessary and precise standards of efficacy on the basis of taking into account the protection of the general public.
the meaning of China's basic drugs continue to be in line with international standards, no longer limited to generic drugs, more high-value patented drugs such as anti-tumor targeted drugs are included.
With the continuous reform of medical insurance payment methods such as payment by disease and total advance payment, the guidance of the base drug catalogue will become stronger and stronger from the point of view of ensuring supply and guiding clinical rational drug use, which will promote the release of varieties to a certain extent.
。